Scott Struthers

R. Scott Struthers (CEO & Chief Scientific Officer) is a Founder of Crinetics Pharmaceuticals. Dr. Struthers received his Ph.D. in Physiology and Pharmacology from the University of California, San Diego, under the supervision of Professor Wylie Vale. Following his degree, he led contract research efforts at Biosym Technologies developing and applying computational tools for drug discovery. He then cofounded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. From 1998 to 2008 he held a series of positions at Neurocrine Biosciences, most recently as Senior Director and Head, Endocrinology and Metabolism. There he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists. This resulted in a first-in-class compound, elagolix, that has demonstrated good safety and efficacy in over 40 clinical trials totaling more than 3000 patients including a 6-month, 872 patient recently completed Phase III study. In 2008, he founded Crinetics Pharmaceuticals to focus on discovery and development of drugs targeting neuropeptide receptors for the treatment of endocrine related diseases and cancers. Dr. Struthers is an author of more than 75 scientific publications.

Scott Struthers is the Co-Founder and CEO at Crinetics Pharmaceuticals, based in United States, North America. With a background in Biotechnology, Scott Struthers has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.